EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008. The conference is being held at the New York Palace Hotel.
ViroPharma also announced that Colin Broom, vice president, chief scientific officer of ViroPharma will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19, 2008. The conference is being held at the St. Regis Hotel in New York.
William Roberts, vice president, corporate communications of ViroPharma will present at the Needham & Company Focus on Infectious Disease Conference at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held at Needham & Company's corporate headquarters in New York.
ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved